In this report, we show that activation of RORγ with small molecule, synthetic agonists enhances T cell effector functions and decreases immune suppressive mechanisms, leading to improved antitumor efficacy in adoptive cell therapy (ACT) models and in syngeneic murine tumor models. The gene discussed is RORC; the disease is neoplasm.